Korro Bio, Inc.
NASDAQ:KRROBiotechnology
+$1.76 today
- Market cap
- $170.75M
- Beta
- 2.10
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$9.79
Volume 0.16M
Average 0.15M
KRRO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Korro Bio, Inc.NASDAQ: KRRO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $380K fell 69.0% year over year, behind the -15.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 41.4% from the prior quarter. Over 3 fiscal years it compounded at +19.5% a year.
Context
- Depreciation & amortization amounted to 67.0% of revenue in FY2025, down 90.0 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -69.0% toward the trailing-twelve-month pace of -15.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 4.28M USD
- Year-over-year change
- +20.1%
- 4-year CAGR
- +2.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.28M | +20.1% |
| FY2024 | 2024-12-31 | 3.57M | -1.8% |
| FY2023 | 2023-12-31 | 3.63M | +44.6% |
| FY2022 | 2022-12-31 | 2.51M | -34.6% |
| FY2021 | 2021-12-31 | 3.84M | — |
Depreciation & Amortization vs competitors
How KRRO compares with its peers on the latest reported figures
- KRRO's LTM Mar 2026 depreciation & amortization of $3.44M is the 2nd highest of the 11 companies compared; the peer median is $637.5K.
- Its year-over-year change of -15.5% is the 8th highest of 9, against a peer median of +2.5%.
- Depreciation & amortization amounts to 89.4% of revenue for KRRO, versus a peer median of 62.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.36M | +53.3% | -27.5% | — | |
| LTM Mar 2026 | $3.44M | -15.5% | +19.5% | 89.4% | |
| LTM Mar 2026 | $3.06M | +36.2% | +7.2% | — | |
| LTM Mar 2026 | $2.93M | -1.6% | -0.7% | 1.4% | |
| LTM Mar 2026 | $1.13M | -6.8% | -1.4% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $670K | +79.6% | +28.8% | — |
| LTM Mar 2026 | $605K | +5.0% | +24.6% | — | |
| LTM Mar 2026 | $577.79K | — | +4.5% | 62.7% | |
| LTM Mar 2026 | $326K | +0.0% | +3.2% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $325.5K | — | +443.4% | — |
| LTM Mar 2026 | $106K | -33.8% | -39.0% | 294.4% | |
| Peer median (excluding KRRO) | $637.5K | +2.5% | +3.9% | 62.7% | |
Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.07M | 0 | 0 | 2.27M | 6.39M |
| Cost of Revenue | 3.84M | 0 | 0 | 0 | 4.28M |
| Gross Profit | 10.23M | 0 | 0 | 2.27M | 2.11M |
| Gross Margin | 72.7% | — | — | 100.0% | 33.0% |
| Research & Development | 59.32M | 42.2M | 57.25M | 63.64M | 65.58M |
| Selling, General & Admin | 34.93M | 16.8M | 36.54M | 30.55M | 28.16M |
| Operating Expenses | 94.26M | 59M | 84.53M | 94.18M | 89.45M |
| Depreciation & Amortization | 3.84M | 2.51M | 3.63M | 3.57M | 4.28M |
| EBITDA | (80.07M) | (56.49M) | (80.9M) | (88.35M) | (83.06M) |
| EBITDA Margin | -569.1% | — | — | -3890.1% | -1299.5% |
| Operating Income | (84.03M) | (59M) | (84.53M) | (91.91M) | (87.34M) |
| Operating Margin | -597.3% | — | — | -4047.1% | -1366.4% |
| Interest Income | 397K | 947K | 0 | 0 | 0 |
| Interest Expense | 764K | 118K | 0 | 0 | 0 |
| Other Income / Expenses | (640K) | 976K | 3.39M | 8.47M | (29.28M) |
| Income Before Tax | (84.67M) | (58.02M) | (81.15M) | (83.44M) | (116.62M) |
| Pre-Tax Margin | -601.9% | — | — | -3674.2% | -1824.5% |
| Income Tax Expense | 15K | 10K | 27K | 141K | 637K |
| Net Income | (84.69M) | (58.03M) | (81.17M) | (83.58M) | (117.26M) |
| Net Margin | -602.0% | — | — | -3680.4% | -1834.5% |
| EPS (Basic) | (4.94) | (227.58) | (53.09) | (9.37) | (12.48) |
| EPS (Diluted) | (4.94) | (227.42) | (53.08) | (9.37) | (12.48) |
| Weighted Avg Shares | 4.45M | 255K | 1.53M | 8.92M | 9.4M |
| Weighted Avg Shares (Diluted) | 4.45M | 255.17K | 1.53M | 8.92M | 9.4M |
Korro Bio, Inc.
NASDAQ:KRRO
Intrinsic Alpha fair value
Locked
Current Price
$12.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.